logo
Plus   Neg
Share
Email

Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent - Quick Facts

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi announced the European Medicines Agency's Committee has recommended to extend the approval for Dupixent to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. Dupixent is currently approved for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

Regeneron and Sanofi are also studying dupilumab in a broad range of clinical development programs for diseases driven by allergic and other type 2 inflammation.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Millennials and Generation Zs, or people aged between 18 to 34 year, pay more for car repairs, according to a new survey. The average American spent $1,986 over the past five years on vehicle repairs and maintenance, according to a survey by Ally Financial conducted by Harris Poll. However, among... Gap Inc.'s (GPS) Old Navy brand announced plans to open 800 new stores as part of its upcoming split from its parent company. "We'll almost double our fleet to 2,000 stores in North America, predominantly in under-served small markets," Old Navy CEO Sonia Syngal said. The company said the plan was... Google has launched a new website called 'Recover Together,' a resource intended to help people recover from addiction or substance use disorder. The new service was launched by the search giant in recognition of the National Recovery Month in September. Google noted that more than 23 million Americans are recovering from addiction, while 20 million are still struggling to seek treatment.
Follow RTT